ClinicalTrials.gg
Not yet recruitingNCT07589686ZYNERGYUpdated Nov 3, 2026

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

A Phase 2 interventional study of Petrelintide and Enicepatide in Obesity or Overweight, sponsored by Hoffmann-La Roche. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Nov 3, 2026Start date movedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
486
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.

Planned enrollment
7th of 21
486 · median 300
Started
2026
with 7 others
Phase 2
7 of 21
1 open now
Primary completion
2027-11
later than 4 of 11 live
Registered
16th of 21
by date

Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 7th largest by planned enrollment, is one of 8 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 16th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.

03

Conditions studied

  • Obesity or Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female participants with (BMI) ≥ 30 kg/m² OR BMI ≥ 27 kg/m² to \< 30 kg/m² with at least one weight-related comorbidity
  • History of at least one self-reported unsuccessful dietary effort to lose body weight

Key Exclusion Criteria:

  • ≥ 48 mmol/mol (6.5%) at screening
  • History of Type 1 or Type 2 Diabetes
  • Self-reported change in body weight > 5 kg within 90 days prior to screening
  • Previous or planned obesity treatment with surgery (excluding liposuction, cryolipolysis, or abdominoplasty if performed > 1 year prior to or during screening)
  • Previous or planned endoscopic and/or device-based obesity treatment or removal or device within the last 6 months prior to screening (e.g., mucosal ablation, gastric artery embolization, intragastric balloon and duodenal-jejunal endoluminal liner)
  • Treatment with any GLP-1 receptor agonist, GLP-1/GIP receptor agonist (or any other GLP-1 based treatment) within 180 days prior to or during screening
  • Current or previous treatment with petrelintide or any other amylin analog
  • Obesity induced by Cushing syndrome or a diagnosis of monogenetic or syndromic forms of obesity
  • History of severe psychiatric disorders
  • History of any hematologic conditions that may interfere with HbA1c measurement
  • Known history or presence of pancreatitis
  • Known gastric emptying abnormality or chronic treatment that affects GI motility
  • Functional Classification IV heart failure
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within the time frame in which is required
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
486 participants (estimated)

Study arms

  • Experimental
    Arm 1: Petrelintide + Enicepatide Dosing Regimen 1

    Combination Product: Petrelintide · Combination Product: Enicepatide

  • Experimental
    Arm 2: Petrelintide + Enicepatide Dosing Regimen 2

    Combination Product: Petrelintide · Combination Product: Enicepatide

  • Experimental
    Arm 3: Petrelintide + Enicepatide Dosing Regimen 3

    Combination Product: Petrelintide · Combination Product: Enicepatide

  • Experimental
    Arm 4: Petrelintide-matching Placebo + Enicepatide

    Combination Product: Enicepatide · Combination Product: Petrelintide-matching Placebo

  • Experimental
    Arm 5: Petrelintide + Enicepatide-matching Placebo

    Combination Product: Petrelintide · Combination Product: Enicepatide-matching Placebo

  • Placebo comparator
    Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo

    Combination Product: Petrelintide-matching Placebo · Combination Product: Enicepatide-matching Placebo

Interventions

  • Combination productPetrelintide

    Petrelintide will be administered subcutaneously to participants once weekly

    Also known as: RO7895515, ZP8396

  • Combination productEnicepatide

    Enicepatide will be administered subcutaneously to participants once weekly

    Also known as: RO7795068, CT-388, RG6640

  • Combination productPetrelintide-matching Placebo

    Matching placebo to Petrelintide will be administered subcutaneously to participants once weekly

  • Combination productEnicepatide-matching Placebo

    Matching placebo to Enicepatide will be administered subcutaneously to participants once weekly

06

What researchers measure

Primary outcomes

  1. Percentage Change in Body Weight between Arms 1 and 6

    Time frame: From Baseline to Week 40

Secondary outcomes

  1. Percentage Change in Body Weight between Arms 2, 3 and Arm 6

    Time frame: From Baseline to Week 40

  2. Percentage Change in Body Weight between Arms 1, 2, 3 and Arms 4, 5

    Time frame: From Baseline to Week 40

  3. Percentage of Participants Achieving Body Weight Loss

    Time frame: From Baseline to Week 40

  4. Change in Body Weight (kilograms [kg])

    Time frame: From Baseline to Week 40

  5. Change in Body Mass Index (kilograms per square meter [kg/m²])

    Time frame: From Baseline to Week 40

  6. Change in Waist Circumference (centimeter [cm])

    Time frame: From Baseline to Week 40

  7. Change in Hemoglobin A1c (HbA1c) (percentage-points)

    Time frame: From Baseline to Week 40

  8. Change in Fasting Insulin

    Time frame: From Baseline to Week 40

  9. Change in Fasting Glucose

    Time frame: From Baseline to Week 40

  10. Change in Systolic Blood Pressure

    Time frame: From Baseline to Week 40

  11. Change in Diastolic Blood Pressure

    Time frame: From Baseline to Week 40

  12. Change in High-Density Lipoprotein (HDL) Cholesterol

    Time frame: From Baseline to Week 40

  13. Change in Low-Density Lipoprotein (LDL) Cholesterol

    Time frame: From Baseline to Week 40

  14. Change in Very-Low-Density Lipoprotein (VLDL) Cholesterol

    Time frame: From Baseline to Week 40

  15. Change in Non-HDL Cholesterol

    Time frame: From Baseline to Week 40

  16. Change in Total Cholesterol

    Time frame: From Baseline to Week 40

  17. Change in Free Fatty Acids

    Time frame: From Baseline to Week 40

  18. Change in Triglycerides

    Time frame: From Baseline to Week 40

  19. Change in High-Sensitivity C-reactive Protein (hsCRP)

    Time frame: From Baseline to Week 40

  20. Number of Participants with Adverse Events (AEs)

    Time frame: From Baseline to Week 40

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 11 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 15, 2026
StartEst.
Nov 30, 2026was Sep 2026
Primary completionEst.
Nov 12, 2027
CompletionEst.
Jan 31, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 30, 2026→Nov 30, 2026
Nov 3, 2026
Interventions
Added Combination product: Petrelintide·Combination product: Petrelintide-matching Placebo; removed Drug: Petrelintide·Drug: Petrelintide-matching Placebo
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Start date Sep 30, 2026→Nov 30, 2026
    Interventions Added Combination product: Petrelintide·Combination product: Petrelintide-matching Placebo; removed Drug: Petrelintide·Drug: Petrelintide-matching Placebo
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07589686
Lead sponsor
Hoffmann-La Roche
Collaborators
Zealand Pharma
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 12, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Reference Study ID Number: CC46372 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Petrelintide · Enicepatide

Start the discussion